© 2003 by Oxford University Press
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2003 Oxford University Press
NEWS |
Evidence of Efficacy: Researchers Investigating Markers for Angiogenesis Inhibitors
| The first 150 words of the full text of this article appear below. |
In June, results of a large phase III trial with the antiangiogenesis drug Avastin (bevacizumab) showed that patients with metastatic colorectal cancer taking the drug with standard chemotherapy lived 4 months longer than those taking chemotherapy alone. And in August, a phase II study demonstrated that patients with metastatic renal cancer who took Avastin had a greater time to tumor progression than those taking a placebo, although there was no difference in survival time between the two groups.
Although antiangiogenesis pioneer Judah Folkman, M.D., called the positive results "a watershed," moving ahead with studies of angiogenesis inhibitors will require developing reliable biomarkers for treatment with antiangiogenesis drugs. "As yet, there are no agreed-upon surrogate markers for angiogenesis inhibitor efficacy," said Folkman, of Children’s Hospital, Boston. "It’s the next big thing."
Traditional chemotherapy drugs are used at the maximum tolerated dose, which is determined by toxicity. However, many angiogenesis inhibitors in
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  D. R. Yance Jr and S. M. Sagar Targeting Angiogenesis With Integrative Cancer Therapies Integr Cancer Ther, March 1, 2006; 5(1): 9 - 29. [Abstract] [PDF]
|
|